首页 > 最新文献

Current drug discovery technologies最新文献

英文 中文
Computational Screening of Novel Nitroimidazole Candidates: Targeting Key Enzymes of Oral Anaerobes for Anti-Parasitic Potential. 新型硝基咪唑候选化合物的计算筛选:针对口腔厌氧菌关键酶的抗寄生虫潜力。
Pub Date : 2024-11-05 DOI: 10.2174/0115701638326365241029080310
Touhami Lanez, Maroua Lanez, Riad Lanez, Elhafnaoui Lanez, Badia Talbi-Lanez

Background: The study focuses on evaluating the parasitic potential of novel metronidazole analogs using computational methods. Specifically, it aims to target key enzymes of oral anaerobes, including UDP-N-acetylglucosamine 1-carboxyvinyltransferase (MurA) of Fusobacterium nucleatum and DNA topoisomerase (Topo) of Prevotella intermedia.

Objective: The objective is to assess the pharmacokinetic and toxicity properties of 368 novel nitroimidazole candidates through virtual screening. Additionally, the study aims to determine the binding affinity of the most promising candidates with the target proteins through molecular docking analyses.

Methods: A combinatorial library of nitroimidazole candidates was constructed, and virtual screening was performed. Molecular docking analyses were conducted to evaluate the binding affinity of selected compounds with MurA and Topo. Further investigation involved molecular dynamic simulation to assess the stability of the compounds within the active sites of MurA and Topo.

Results: All selected compounds exhibited activity against both MurA and Topo. Among them, Mnz11, Mnz12, and Mnz15 demonstrated the lowest binding free energies and IC50 values. Molecular dynamic simulation indicated that these three compounds remained stable within the active sites of MurA and Topo, with RMSD values consistently below 2Å. Additionally, the antibacterial potential of the most potent compound, Mnz15, was evaluated against a series of oral microbes.

Conclusion: The study concludes that the newly identified nitroimidazole candidates show promise as anti-parasitic agents, based on their activity against key enzymes of oral anaerobes and their pharmacokinetic properties evaluated through computational methods.

背景:本研究的重点是利用计算方法评估新型甲硝唑类似物的寄生潜力。具体来说,它以口腔厌氧菌的关键酶为目标,包括核酸镰刀菌的 UDP-N- 乙酰葡萄糖胺 1-羧基乙烯基转移酶(MurA)和中间普雷沃菌的 DNA 拓扑异构酶(Topo):目的:通过虚拟筛选评估 368 种新型硝基咪唑候选药物的药代动力学和毒性特性。此外,该研究还旨在通过分子对接分析确定最有希望的候选化合物与靶蛋白的结合亲和力:方法:构建了硝基咪唑候选化合物组合库,并进行了虚拟筛选。进行了分子对接分析,以评估所选化合物与 MurA 和 Topo 的结合亲和力。进一步的研究包括分子动态模拟,以评估化合物在 MurA 和 Topo 活性位点内的稳定性:结果:所有选定的化合物都对 MurA 和 Topo 具有活性。其中,Mnz11、Mnz12 和 Mnz15 的结合自由能和 IC50 值最低。分子动力学模拟表明,这三种化合物在 MurA 和 Topo 的活性位点内保持稳定,RMSD 值始终低于 2 Å。此外,还评估了最强化合物 Mnz15 对一系列口腔微生物的抗菌潜力:研究得出结论:新发现的硝基咪唑候选化合物对口腔厌氧菌的关键酶具有活性,而且通过计算方法评估了它们的药代动力学特性,因此有望成为抗寄生虫药物。
{"title":"Computational Screening of Novel Nitroimidazole Candidates: Targeting Key Enzymes of Oral Anaerobes for Anti-Parasitic Potential.","authors":"Touhami Lanez, Maroua Lanez, Riad Lanez, Elhafnaoui Lanez, Badia Talbi-Lanez","doi":"10.2174/0115701638326365241029080310","DOIUrl":"10.2174/0115701638326365241029080310","url":null,"abstract":"<p><strong>Background: </strong>The study focuses on evaluating the parasitic potential of novel metronidazole analogs using computational methods. Specifically, it aims to target key enzymes of oral anaerobes, including UDP-N-acetylglucosamine 1-carboxyvinyltransferase (MurA) of Fusobacterium nucleatum and DNA topoisomerase (Topo) of Prevotella intermedia.</p><p><strong>Objective: </strong>The objective is to assess the pharmacokinetic and toxicity properties of 368 novel nitroimidazole candidates through virtual screening. Additionally, the study aims to determine the binding affinity of the most promising candidates with the target proteins through molecular docking analyses.</p><p><strong>Methods: </strong>A combinatorial library of nitroimidazole candidates was constructed, and virtual screening was performed. Molecular docking analyses were conducted to evaluate the binding affinity of selected compounds with MurA and Topo. Further investigation involved molecular dynamic simulation to assess the stability of the compounds within the active sites of MurA and Topo.</p><p><strong>Results: </strong>All selected compounds exhibited activity against both MurA and Topo. Among them, Mnz11, Mnz12, and Mnz15 demonstrated the lowest binding free energies and IC50 values. Molecular dynamic simulation indicated that these three compounds remained stable within the active sites of MurA and Topo, with RMSD values consistently below 2Å. Additionally, the antibacterial potential of the most potent compound, Mnz15, was evaluated against a series of oral microbes.</p><p><strong>Conclusion: </strong>The study concludes that the newly identified nitroimidazole candidates show promise as anti-parasitic agents, based on their activity against key enzymes of oral anaerobes and their pharmacokinetic properties evaluated through computational methods.</p>","PeriodicalId":93962,"journal":{"name":"Current drug discovery technologies","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142590774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preliminary Characterization of the Vasorelaxant Effect of Thymus atlanticus (Ball) Roussine Using Optical Methods. 用光学方法初步鉴定大西洋胸腺(波尔)鲁辛的血管舒张效果
Pub Date : 2024-11-04 DOI: 10.2174/0115701638309612240726060844
Hamza Elbouny, Nabil Bouchebchoub, Brahim Ouahzizi, Rania Hajjami, Younes Filali-Zegzouti, Mohamed Yassine Amarouch, Chakib Alem

Background: Thymus atlanticus (Ball) Roussine is a Moroccan endemic thyme species that is traditionally used as an aromatic and medicinal plant. Several studies have demonstrated its pharmacological significance and therapeutic value.

Objective: The current study aimed to assess the vasorelaxant effect of the aqueous extract of this species.

Methods: The contractility of isolated rat aortas was investigated using the multi-well organ bath technique. This method was adapted and validated in our experimental conditions using epinephrine and hydralazine as vasoconstrictive and vasodilator agents, respectively. The application of 10 μM epinephrine induced a clear vasoconstriction of the aorta rings (Lumen reduction = 31.8±0.4%). However, hydralazine induced a dose-dependent relaxation with an EC50 value of 6.1±1.2 mM. For the aqueous extract of T. atlanticus, the aortic rings were precontracted with epinephrine, and then increasing concentrations (0.125-1 mg/mL) of this extract were added cumulatively.

Results: The results have indicated T. atlanticus extract to have a significant vasodilatory effect in a dose-dependent manner (EC50 = 0.52±0.03 mg/mL).

Conclusion: The findings provide preliminary evidence of the vasorelaxant effect of the aqueous extract of T. atlanticus using a low-cost optical approach. However, the cellular and molecular mechanisms underlying this effect have yet to be revealed.

背景:Thymus atlanticus (Ball) Roussine 是摩洛哥特有的百里香品种,传统上被用作芳香植物和药用植物。多项研究证明了其药理意义和治疗价值:本研究旨在评估该物种水提取物的血管舒张作用:方法:采用多孔器官浴技术研究了离体大鼠主动脉的收缩能力。在我们的实验条件下,使用肾上腺素和肼屈嗪分别作为血管收缩剂和血管扩张剂,对该方法进行了调整和验证。应用 10 μM 肾上腺素可引起主动脉环明显的血管收缩(管腔缩小 = 31.8±0.4%)。然而,肼屈嗪可诱导剂量依赖性松弛,其 EC50 值为 6.1±1.2 mM。对于大西洋金枪鱼的水提取物,先用肾上腺素预收缩主动脉环,然后逐渐加入浓度越来越高(0.125-1 mg/mL)的该提取物:结果:结果表明,大西洋金枪鱼提取物具有显著的血管扩张作用,且呈剂量依赖性(EC50 = 0.52±0.03 mg/mL):结论:研究结果提供了使用低成本光学方法检测大西洋金枪鱼水提取物的血管舒张效果的初步证据。然而,这种作用的细胞和分子机制仍有待揭示。
{"title":"Preliminary Characterization of the Vasorelaxant Effect of Thymus atlanticus (Ball) Roussine Using Optical Methods.","authors":"Hamza Elbouny, Nabil Bouchebchoub, Brahim Ouahzizi, Rania Hajjami, Younes Filali-Zegzouti, Mohamed Yassine Amarouch, Chakib Alem","doi":"10.2174/0115701638309612240726060844","DOIUrl":"https://doi.org/10.2174/0115701638309612240726060844","url":null,"abstract":"<p><strong>Background: </strong>Thymus atlanticus (Ball) Roussine is a Moroccan endemic thyme species that is traditionally used as an aromatic and medicinal plant. Several studies have demonstrated its pharmacological significance and therapeutic value.</p><p><strong>Objective: </strong>The current study aimed to assess the vasorelaxant effect of the aqueous extract of this species.</p><p><strong>Methods: </strong>The contractility of isolated rat aortas was investigated using the multi-well organ bath technique. This method was adapted and validated in our experimental conditions using epinephrine and hydralazine as vasoconstrictive and vasodilator agents, respectively. The application of 10 μM epinephrine induced a clear vasoconstriction of the aorta rings (Lumen reduction = 31.8±0.4%). However, hydralazine induced a dose-dependent relaxation with an EC50 value of 6.1±1.2 mM. For the aqueous extract of T. atlanticus, the aortic rings were precontracted with epinephrine, and then increasing concentrations (0.125-1 mg/mL) of this extract were added cumulatively.</p><p><strong>Results: </strong>The results have indicated T. atlanticus extract to have a significant vasodilatory effect in a dose-dependent manner (EC50 = 0.52±0.03 mg/mL).</p><p><strong>Conclusion: </strong>The findings provide preliminary evidence of the vasorelaxant effect of the aqueous extract of T. atlanticus using a low-cost optical approach. However, the cellular and molecular mechanisms underlying this effect have yet to be revealed.</p>","PeriodicalId":93962,"journal":{"name":"Current drug discovery technologies","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142585213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AI in Clinical Trials and Drug Development: Challenges and Potential Advancements. 人工智能在临床试验和药物开发中的应用:挑战与潜在进步。
Pub Date : 2024-10-28 DOI: 10.2174/0115701638314252241016165345
Divyanshi Gupta, Pranay Wal, Ankita Wal, Sribhavani K R, Mudit Kumar, Krishna Chandra Panda, Mukesh Chandra Sharma

Artificial intelligence (AI) is one of the fastest-growing fields in various industries, including engineering, architecture, medical and clinical research, aerospace, and others. AI, which is a combination of machine learning (ML), deep learning (DL), and human intelligence (HI), is revolutionizing drug discovery and development by making it more cost-effective and efficient. It is also being used in fields such as medicinal chemistry, molecular and cell biology, pharmacology, pharmacokinetics, formulation development, and toxicology. AI plays a crucial role in clinical testing by enhancing patient stratification, patient sample evaluation, and trial design, assisting in the identification of biomarkers, determining efficacy criteria, dose selection, trial length, and target patient population selection. The primary objective of this study is to emphasize the importance of AI in clinical trials and drug development, while also exploring the existing challenges and potential advancements in AI within the healthcare industry. A comprehensive literature review was conducted, covering the period from 1998 to 2023. The Science Direct, PubMed, and Google Scholar databases were searched for relevant information. A variety of publications, including Research Gate, Nature, MDPI, and Springer Link, provided pertinent data. This study aimed to gain a deeper understanding of the use of AI in clinical research and drug development, as well as its potential and limitations. We also discuss the benefits and main data limitations of the traditional trial and drug development approach. AI approaches are currently being used to overcome research obstacles and eliminate conceptual or methodological limitations. After discussing possible obstacles and coping mechanisms, we provide several recommendations to help individuals understand the challenges and difficulties associated with clinical research and drug development. It is essential for pharmaceutical companies to have a cutting-edge AI strategy if AI is to become a routine tool for clinical research and drug development.

人工智能(AI)是各行各业发展最快的领域之一,包括工程、建筑、医学和临床研究、航空航天等。人工智能是机器学习(ML)、深度学习(DL)和人类智能(HI)的结合,它正在彻底改变药物的发现和开发,使其更具成本效益和效率。它还被用于药物化学、分子和细胞生物学、药理学、药物动力学、制剂开发和毒理学等领域。人工智能在临床测试中发挥着至关重要的作用,它可以加强患者分层、患者样本评估和试验设计,协助识别生物标记物,确定疗效标准、剂量选择、试验长度和目标患者人群选择。本研究的主要目的是强调人工智能在临床试验和药物开发中的重要性,同时探讨人工智能在医疗保健行业中的现有挑战和潜在进步。我们进行了全面的文献综述,时间跨度从 1998 年到 2023 年。我们在 Science Direct、PubMed 和 Google Scholar 数据库中搜索了相关信息。包括 Research Gate、Nature、MDPI 和 Springer Link 在内的各种出版物提供了相关数据。本研究旨在深入了解人工智能在临床研究和药物开发中的应用及其潜力和局限性。我们还讨论了传统试验和药物开发方法的优势和主要数据限制。目前正在使用人工智能方法来克服研究障碍,消除概念或方法上的局限性。在讨论了可能存在的障碍和应对机制后,我们提出了几项建议,以帮助个人了解与临床研究和药物开发相关的挑战和困难。如果人工智能要成为临床研究和药物开发的常规工具,制药公司就必须制定最前沿的人工智能战略。
{"title":"AI in Clinical Trials and Drug Development: Challenges and Potential Advancements.","authors":"Divyanshi Gupta, Pranay Wal, Ankita Wal, Sribhavani K R, Mudit Kumar, Krishna Chandra Panda, Mukesh Chandra Sharma","doi":"10.2174/0115701638314252241016165345","DOIUrl":"https://doi.org/10.2174/0115701638314252241016165345","url":null,"abstract":"<p><p>Artificial intelligence (AI) is one of the fastest-growing fields in various industries, including engineering, architecture, medical and clinical research, aerospace, and others. AI, which is a combination of machine learning (ML), deep learning (DL), and human intelligence (HI), is revolutionizing drug discovery and development by making it more cost-effective and efficient. It is also being used in fields such as medicinal chemistry, molecular and cell biology, pharmacology, pharmacokinetics, formulation development, and toxicology. AI plays a crucial role in clinical testing by enhancing patient stratification, patient sample evaluation, and trial design, assisting in the identification of biomarkers, determining efficacy criteria, dose selection, trial length, and target patient population selection. The primary objective of this study is to emphasize the importance of AI in clinical trials and drug development, while also exploring the existing challenges and potential advancements in AI within the healthcare industry. A comprehensive literature review was conducted, covering the period from 1998 to 2023. The Science Direct, PubMed, and Google Scholar databases were searched for relevant information. A variety of publications, including Research Gate, Nature, MDPI, and Springer Link, provided pertinent data. This study aimed to gain a deeper understanding of the use of AI in clinical research and drug development, as well as its potential and limitations. We also discuss the benefits and main data limitations of the traditional trial and drug development approach. AI approaches are currently being used to overcome research obstacles and eliminate conceptual or methodological limitations. After discussing possible obstacles and coping mechanisms, we provide several recommendations to help individuals understand the challenges and difficulties associated with clinical research and drug development. It is essential for pharmaceutical companies to have a cutting-edge AI strategy if AI is to become a routine tool for clinical research and drug development.</p>","PeriodicalId":93962,"journal":{"name":"Current drug discovery technologies","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142549642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Update on Clinically Evaluated Medicinal Plants for Psoriasis Management. 经临床评估可用于治疗牛皮癣的药用植物的最新进展。
Pub Date : 2024-10-28 DOI: 10.2174/0115701638327441241016014503
Ramin Ansari, Mahkameh Moradi Mehrabadi, Mahnaz Sadat Hosseini, Mehdi Ghahartars, Mohammad Mehdi Zarshenas

Psoriasis is a prevalent inflammatory disease affecting almost 0.5-5 % of the world population. Multiple treatment approaches have been developed to manage psoriasis so far. Although concerns exist in the long-term usage of conventional and biological agents in terms of safety, effectiveness, expensiveness, and tolerability, complementary and alternative medicine (CAM) is a promising point of view for future psoriasis management. In this study, databases including Scopus, PubMed, Google Scholar, and Web of Science were searched for relevant literature on herbal medications clinically evaluated for psoriasis, especially those originating from traditional medicine. About 40 relevant papers were selected by March 2023. Most of the studies were clinical trials on poly-herbal formulations from traditional Chinese medicine (TCM). There are controversial results regarding the efficacy of these herbal formulations in psoriasis mainly due to the variation in the study design. Moreover, the probable protective mechanisms and responsible herbal metabolites of these formulations are summarized. There is a global need for more in-vitro and in-vivo studies based on the standard protocols in terms of the evaluation of the safety and efficacy of topical/ systemic herbal preparations for psoriasis.

银屑病是一种常见的炎症性疾病,影响着全球近 0.5%-5% 的人口。迄今为止,已开发出多种治疗银屑病的方法。虽然长期使用传统药物和生物制剂在安全性、有效性、经济性和耐受性方面存在问题,但补充和替代医学(CAM)是未来治疗银屑病的一个有前途的观点。本研究在 Scopus、PubMed、Google Scholar 和 Web of Science 等数据库中搜索了对银屑病进行临床评估的草药相关文献,尤其是源自传统医学的草药。截至 2023 年 3 月,共筛选出约 40 篇相关论文。大多数研究都是关于传统中药多草药配方的临床试验。这些中草药配方对银屑病的疗效存在争议,主要原因是研究设计不同。此外,还总结了这些配方的可能保护机制和主要草药代谢物。在评估银屑病外用/内服草药制剂的安全性和疗效方面,全球需要根据标准方案开展更多的体外和体内研究。
{"title":"An Update on Clinically Evaluated Medicinal Plants for Psoriasis Management.","authors":"Ramin Ansari, Mahkameh Moradi Mehrabadi, Mahnaz Sadat Hosseini, Mehdi Ghahartars, Mohammad Mehdi Zarshenas","doi":"10.2174/0115701638327441241016014503","DOIUrl":"https://doi.org/10.2174/0115701638327441241016014503","url":null,"abstract":"<p><p>Psoriasis is a prevalent inflammatory disease affecting almost 0.5-5 % of the world population. Multiple treatment approaches have been developed to manage psoriasis so far. Although concerns exist in the long-term usage of conventional and biological agents in terms of safety, effectiveness, expensiveness, and tolerability, complementary and alternative medicine (CAM) is a promising point of view for future psoriasis management. In this study, databases including Scopus, PubMed, Google Scholar, and Web of Science were searched for relevant literature on herbal medications clinically evaluated for psoriasis, especially those originating from traditional medicine. About 40 relevant papers were selected by March 2023. Most of the studies were clinical trials on poly-herbal formulations from traditional Chinese medicine (TCM). There are controversial results regarding the efficacy of these herbal formulations in psoriasis mainly due to the variation in the study design. Moreover, the probable protective mechanisms and responsible herbal metabolites of these formulations are summarized. There is a global need for more in-vitro and in-vivo studies based on the standard protocols in terms of the evaluation of the safety and efficacy of topical/ systemic herbal preparations for psoriasis.</p>","PeriodicalId":93962,"journal":{"name":"Current drug discovery technologies","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142549643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In Vitro Antibacterial Activity of Adiantum capillus Veneris Extraction with Methanol, Chloroform, and Ether Solvents against Methicillin-resistant Staphylococcus aureus. 用甲醇、氯仿和乙醚溶剂提取的 Adiantum capillus Veneris 对耐甲氧西林金黄色葡萄球菌的体外抗菌活性。
Pub Date : 2024-10-25 DOI: 10.2174/0115701638313570241015045118
Mahdiyeh Ebrahimzadeh, Solmaz Rahbari, Reza Hosseini Doust, Faraz Mojab

Background: The increasing problem of multi-drug resistant (MDR) pathogens is a worldwide concern, especially in the pharmaceutical industry. At the same time, medicinal plants have renewed interest because of their wide variety of bioactive phytochemicals, which could be used to develop new antimicrobial drugs. This renewed interest is partly due to the growing resistance to traditional drugs and their associated side effects.

Methods: The objective of this study is to assess the antimicrobial properties of the total extract and various fractions of Adiantum capillus veneris against Methicillin-resistant Staphylococcus aureus (MRSA). The aerial parts of Adiantum capillus veneris were subjected to extraction using methanol, chloroform, and ether, and the resulting extracts were tested for their antimicrobial activity against MRSA. Additionally, essential oil was obtained from the aerial parts using a Clevenger apparatus and boiling water. Furthermore, Gas Chromatography-Mass Spectrometry (GC/MS) was utilized to analyze the phytochemicals isolated from the extracts of Adiantum capillus veneris.

Results: The essential oil was obtained through distillation and then analyzed using GC/MS. The antimicrobial activity was evaluated using the agar diffusion method.

Conclusion: GC/MS analysis revealed that the composition was primarily phytol (59.9%), constituting 99.3% of phyto-constituents. However, both the total extract and the individual fractions exhibited no inhibitory effects against MRSA strains.

背景:多重耐药性(MDR)病原体日益增多的问题已成为全球关注的焦点,尤其是在制药行业。与此同时,药用植物因其种类繁多的生物活性植物化学物质而再次引起人们的兴趣,这些植物化学物质可用于开发新的抗菌药物。人们之所以对药用植物重新产生兴趣,部分原因是人们对传统药物的抗药性和相关副作用越来越大:本研究的目的是评估 Adiantum capillus veneris 的总提取物和各种馏分对耐甲氧西林金黄色葡萄球菌(MRSA)的抗菌特性。使用甲醇、氯仿和乙醚对 Adiantum capillus veneris 的气生部分进行萃取,并测试了萃取物对 MRSA 的抗菌活性。此外,还使用 Clevenger 仪器和沸水从气生部分提取了精油。此外,还利用气相色谱-质谱法(GC/MS)分析了从 Adiantum capillus veneris 提取物中分离出来的植物化学物质:通过蒸馏获得精油,然后用气相色谱/质谱法进行分析。结论:GC/MS 分析表明,从 Adiantum capillus veneris 提取物中分离出的植物化学物质具有很高的抗菌活性:GC/MS 分析表明,精油的主要成分是植物醇(59.9%),占植物成分的 99.3%。然而,总提取物和单个馏分对 MRSA 菌株均无抑制作用。
{"title":"In Vitro Antibacterial Activity of Adiantum capillus Veneris Extraction with Methanol, Chloroform, and Ether Solvents against Methicillin-resistant Staphylococcus aureus.","authors":"Mahdiyeh Ebrahimzadeh, Solmaz Rahbari, Reza Hosseini Doust, Faraz Mojab","doi":"10.2174/0115701638313570241015045118","DOIUrl":"https://doi.org/10.2174/0115701638313570241015045118","url":null,"abstract":"<p><strong>Background: </strong>The increasing problem of multi-drug resistant (MDR) pathogens is a worldwide concern, especially in the pharmaceutical industry. At the same time, medicinal plants have renewed interest because of their wide variety of bioactive phytochemicals, which could be used to develop new antimicrobial drugs. This renewed interest is partly due to the growing resistance to traditional drugs and their associated side effects.</p><p><strong>Methods: </strong>The objective of this study is to assess the antimicrobial properties of the total extract and various fractions of Adiantum capillus veneris against Methicillin-resistant Staphylococcus aureus (MRSA). The aerial parts of Adiantum capillus veneris were subjected to extraction using methanol, chloroform, and ether, and the resulting extracts were tested for their antimicrobial activity against MRSA. Additionally, essential oil was obtained from the aerial parts using a Clevenger apparatus and boiling water. Furthermore, Gas Chromatography-Mass Spectrometry (GC/MS) was utilized to analyze the phytochemicals isolated from the extracts of Adiantum capillus veneris.</p><p><strong>Results: </strong>The essential oil was obtained through distillation and then analyzed using GC/MS. The antimicrobial activity was evaluated using the agar diffusion method.</p><p><strong>Conclusion: </strong>GC/MS analysis revealed that the composition was primarily phytol (59.9%), constituting 99.3% of phyto-constituents. However, both the total extract and the individual fractions exhibited no inhibitory effects against MRSA strains.</p>","PeriodicalId":93962,"journal":{"name":"Current drug discovery technologies","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142549644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Potential Role of Benzoic Acid and its Synthetic Derivatives to Alleviate Cancer: An Up-to-Date Review. 苯甲酸及其合成衍生物在缓解癌症方面的潜在作用:最新综述。
Pub Date : 2024-10-07 DOI: 10.2174/0115701638311865240904054111
Arvind Kumar, Kamal Yt, Arun K Mishra, Mhaveer Singh, Harpreet Singh, Niranjan Kaushik, Amrita Mishra

Unregulated cell division is one of the main causes of cancer. These cancerous cells negatively impact nearby healthy cells. Cancer can occur anywhere in the body. Normal cell division occurs when cells grow, reproduce, and divide as the body needs. As a normal cascade of cell growth and division, when the cells get damaged, they undergo death, and normal cells develop. However, sometimes, this process is not followed, and abnormal or damaged cells start to grow and multiply several times more than normal. This particular process may form the basis of cancer. There is a research gap in terms of identifying personalized synthetic anticancer therapy, which may be based on individual patient characteristics with an aim to optimize treatment efficacy and minimize adverse effects. While searching for new bioactive compounds, it has been observed that organic molecules with benzoic acid (BA) moiety possess significant anticancer potential. Several works of literature reported the use of BA from natural or synthetic sources to synthesize bioactive chemicals. It has been observed that several natural products also contain BA moiety, and the presence of this moiety is considered responsible for several important biological activities. Therefore, in order to chemically synthesize a wide variety of potent biologically active compounds, benzoic acid as a basic moiety in the form of a scaffold can be employed. Other synthetic compounds with BA scaffolds include furosemide, tetracaine, and bumetanide. The current article aims to focus on past and present work done on BA derivatives and to emphasize the molecular pathways involved in cancer treatment. The future prospects for research in this area are encouraging as researchers are striving to advance synthetic BA derivatives. This could possibly contribute to more efficient treatments and better results for cancer patients.

不规则的细胞分裂是导致癌症的主要原因之一。这些癌细胞会对附近的健康细胞产生负面影响。癌症可发生在身体的任何部位。正常的细胞分裂是指细胞根据身体需要生长、繁殖和分裂。作为细胞生长和分裂的正常级联,当细胞受损时,它们就会死亡,正常细胞就会发育。然而,有时这一过程并没有得到遵守,异常或受损的细胞开始比正常细胞多几倍地生长和繁殖。这一特殊过程可能是癌症的基础。在确定个性化合成抗癌疗法方面还存在研究空白,这种疗法可以根据患者的个体特征来确定,目的是优化疗效,减少不良反应。在寻找新的生物活性化合物的过程中,人们发现带有苯甲酸(BA)分子的有机分子具有显著的抗癌潜力。一些文献报道了利用天然或合成来源的苯甲酸合成生物活性化学物质的情况。据观察,一些天然产品也含有 BA 分子,而这一分子的存在被认为是多种重要生物活性的原因。因此,为了化学合成多种具有生物活性的强效化合物,可以采用苯甲酸作为支架形式的基本分子。其他具有 BA 支架的合成化合物包括呋塞米、四卡因和布美他尼。本文旨在重点介绍过去和现在有关 BA 衍生物的工作,并强调癌症治疗所涉及的分子途径。由于研究人员正在努力推进合成 BA 衍生物,该领域未来的研究前景令人鼓舞。这有可能为癌症患者带来更有效的治疗和更好的疗效。
{"title":"Potential Role of Benzoic Acid and its Synthetic Derivatives to Alleviate Cancer: An Up-to-Date Review.","authors":"Arvind Kumar, Kamal Yt, Arun K Mishra, Mhaveer Singh, Harpreet Singh, Niranjan Kaushik, Amrita Mishra","doi":"10.2174/0115701638311865240904054111","DOIUrl":"https://doi.org/10.2174/0115701638311865240904054111","url":null,"abstract":"<p><p>Unregulated cell division is one of the main causes of cancer. These cancerous cells negatively impact nearby healthy cells. Cancer can occur anywhere in the body. Normal cell division occurs when cells grow, reproduce, and divide as the body needs. As a normal cascade of cell growth and division, when the cells get damaged, they undergo death, and normal cells develop. However, sometimes, this process is not followed, and abnormal or damaged cells start to grow and multiply several times more than normal. This particular process may form the basis of cancer. There is a research gap in terms of identifying personalized synthetic anticancer therapy, which may be based on individual patient characteristics with an aim to optimize treatment efficacy and minimize adverse effects. While searching for new bioactive compounds, it has been observed that organic molecules with benzoic acid (BA) moiety possess significant anticancer potential. Several works of literature reported the use of BA from natural or synthetic sources to synthesize bioactive chemicals. It has been observed that several natural products also contain BA moiety, and the presence of this moiety is considered responsible for several important biological activities. Therefore, in order to chemically synthesize a wide variety of potent biologically active compounds, benzoic acid as a basic moiety in the form of a scaffold can be employed. Other synthetic compounds with BA scaffolds include furosemide, tetracaine, and bumetanide. The current article aims to focus on past and present work done on BA derivatives and to emphasize the molecular pathways involved in cancer treatment. The future prospects for research in this area are encouraging as researchers are striving to advance synthetic BA derivatives. This could possibly contribute to more efficient treatments and better results for cancer patients.</p>","PeriodicalId":93962,"journal":{"name":"Current drug discovery technologies","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142396227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Liquisolid Technique for Solubility Enhancement of Poorly Soluble Drug - A Brief Review. 用于提高难溶性药物溶解度的 Liquisolid 技术--简要回顾。
Pub Date : 2024-10-04 DOI: 10.2174/0115701638318659240923074614
Amaresh Prusty, Bikash Ranajn Jena, Vivek Barik, Piyali Khamkat, Bhakti Bhusan Barik

Most of the newly discovered drug candidates are lipophilic and poorly water-soluble, making it a significant challenge for the pharmaceutical industry to formulate suitable drug delivery systems. This review gives insight into an overview of the liquisolid technique (LST) and summarizes the progress of its various applications in drug delivery. This novel technique involves converting liquid drugs or drugs in a liquid state (such as solutions, suspensions, or emulsions) into dry, nonadherent, free-flowing, and readily compressible powder mixtures by blending or spraying a liquid dispersion onto specific powder carriers and coating materials. In Liquisolid systems, the liquid medication is absorbed into the interior framework of carriers. Once the carrier's interior is saturated with liquid medication, a liquid layer forms on the surface of the carrier particles, which is instantly adsorbed by the fine coating material. As a result, a dry, free-flowing, and compressible powder mixture is formed. Compared to other solubility enhancement techniques, s.a. micronization, inclusion complexation, microencapsulation, nanosuspension, and self-nano emulsions, LST is relatively simple to prepare and may offer a cost-effective solution to enhance the solubility of poorly water-soluble drugs enhancing its bioavailability in drug formulation and delivery.

新发现的候选药物大多具有亲脂性且水溶性较差,因此配制合适的给药系统成为制药行业面临的一大挑战。本综述概述了液固技术(LST),并总结了其在给药领域的各种应用进展。这种新型技术是通过将液体分散体混合或喷洒到特定的粉末载体和包衣材料上,将液态药物或液态药物(如溶液、悬浮液或乳剂)转化为干燥、不粘附、自由流动且易于压缩的粉末混合物。在 Liquisolid 系统中,液体药物被吸收到载体的内部结构中。一旦载体内部的药液达到饱和,载体颗粒表面就会形成液层,并立即被精细的涂层材料吸附。这样就形成了一种干燥、自由流动且可压缩的粉末混合物。与其他提高溶解度的技术(如微粉化、包合物络合、微囊化、纳米悬浮和自纳米乳剂)相比,LST 的制备相对简单,可为提高水溶性差的药物的溶解度提供一种具有成本效益的解决方案,从而提高其在药物制剂和给药过程中的生物利用度。
{"title":"Liquisolid Technique for Solubility Enhancement of Poorly Soluble Drug - A Brief Review.","authors":"Amaresh Prusty, Bikash Ranajn Jena, Vivek Barik, Piyali Khamkat, Bhakti Bhusan Barik","doi":"10.2174/0115701638318659240923074614","DOIUrl":"https://doi.org/10.2174/0115701638318659240923074614","url":null,"abstract":"<p><p>Most of the newly discovered drug candidates are lipophilic and poorly water-soluble, making it a significant challenge for the pharmaceutical industry to formulate suitable drug delivery systems. This review gives insight into an overview of the liquisolid technique (LST) and summarizes the progress of its various applications in drug delivery. This novel technique involves converting liquid drugs or drugs in a liquid state (such as solutions, suspensions, or emulsions) into dry, nonadherent, free-flowing, and readily compressible powder mixtures by blending or spraying a liquid dispersion onto specific powder carriers and coating materials. In Liquisolid systems, the liquid medication is absorbed into the interior framework of carriers. Once the carrier's interior is saturated with liquid medication, a liquid layer forms on the surface of the carrier particles, which is instantly adsorbed by the fine coating material. As a result, a dry, free-flowing, and compressible powder mixture is formed. Compared to other solubility enhancement techniques, s.a. micronization, inclusion complexation, microencapsulation, nanosuspension, and self-nano emulsions, LST is relatively simple to prepare and may offer a cost-effective solution to enhance the solubility of poorly water-soluble drugs enhancing its bioavailability in drug formulation and delivery.</p>","PeriodicalId":93962,"journal":{"name":"Current drug discovery technologies","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142396226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In silico Profiling and Pharmacokinetic Modelling of Olivetol: Evaluating its Potential as a Therapeutic Agent for Diabetic Wound Healing. Olivetol 的硅学分析和药代动力学模型:评估其作为糖尿病伤口愈合治疗剂的潜力
Pub Date : 2024-10-01 DOI: 10.2174/0115701638332872240922184903
Nirenjen Shanmugasundaram, Narayanan Jaishankar

Background: Diabetic wound healing poses a significant challenge due to the intricate disruptions in cellular and molecular processes induced by hyperglycaemia, leading to delayed or impaired tissue repair. Computational techniques offer a promising avenue for unravelling the complexities of diabetic wound healing by elucidating the molecular mechanisms involved.

Methodology: This study utilized in silico molecular docking and dynamics simulations to explore the potential therapeutic effectiveness of olivetol, a phenolic compound, in the context of diabetic wound healing. Furthermore, computational methodologies, encompassing pkCSM, Swiss ADME, OSIRIS® property explorer, PASS online web resource, and MOLINSPIRATION® software, were employed to forecast the pharmacokinetic properties, biological actions, and in vitro analyses, such as MTT and scratch assays, to evaluate the therapeutic effectiveness of olivetol in wound healing.

Results and discussion: Our findings have revealed olivetol to be a promising candidate for targeting multiple pathways implicated in diabetic wound healing. Its ability to modulate inflammation, oxidative stress, extracellular matrix remodeling, angiogenesis, and cell signaling suggests a multifaceted approach to promoting effective wound repair. Moreover, olivetol has been found to demonstrate strong binding affinity with key MRSA target proteins, indicating its potential as an antimicrobial agent against MRSA infections in diabetic wounds. The in vitro MTT assay demonstrated cell viability with an IC50 value of 40.80 μM, highlighting its cytotoxicity potential. Additionally, the scratch assay confirmed promising wound healing activity, showcasing its effectiveness in promoting cell migration and closure.

Conclusion: Olivetol emerges as a promising candidate for targeted interventions in non-healing diabetic wounds, particularly due to its ability to address prolonged inflammation, a common obstacle in diabetic wound healing.

背景:由于高血糖引起的细胞和分子过程错综复杂的紊乱,导致组织修复延迟或受损,糖尿病伤口愈合是一项重大挑战。通过阐明糖尿病伤口愈合所涉及的分子机制,计算技术为揭示糖尿病伤口愈合的复杂性提供了一条大有可为的途径:本研究利用分子对接和动力学模拟来探索橄榄醇(一种酚类化合物)在糖尿病伤口愈合方面的潜在治疗效果。此外,我们还采用了包括 pkCSM、Swiss ADME、OSIRIS® Property explorer、PASS 在线网络资源和 MOLINSPIRATION® 软件在内的计算方法来预测药代动力学特性、生物作用和体外分析(如 MTT 和划痕试验),以评估橄榄醇在伤口愈合中的治疗效果:我们的研究结果表明,橄榄醇是一种很有前景的候选药物,可用于靶向与糖尿病伤口愈合有关的多种途径。橄榄醇能够调节炎症、氧化应激、细胞外基质重塑、血管生成和细胞信号传导,这表明橄榄醇能从多方面促进伤口的有效修复。此外,研究还发现橄榄醇与关键的 MRSA 靶蛋白有很强的结合亲和力,这表明橄榄醇具有抗糖尿病伤口中 MRSA 感染的潜力。体外 MTT 试验证明了细胞的活力,其 IC50 值为 40.80 μM,凸显了其细胞毒性潜力。此外,划痕试验也证实了橄榄醇具有良好的伤口愈合活性,显示了它在促进细胞迁移和闭合方面的功效:结论:橄榄醇有望成为糖尿病伤口不愈合靶向干预的候选药物,特别是因为它能够解决糖尿病伤口愈合的常见障碍--长期炎症。
{"title":"In silico Profiling and Pharmacokinetic Modelling of Olivetol: Evaluating its Potential as a Therapeutic Agent for Diabetic Wound Healing.","authors":"Nirenjen Shanmugasundaram, Narayanan Jaishankar","doi":"10.2174/0115701638332872240922184903","DOIUrl":"https://doi.org/10.2174/0115701638332872240922184903","url":null,"abstract":"<p><strong>Background: </strong>Diabetic wound healing poses a significant challenge due to the intricate disruptions in cellular and molecular processes induced by hyperglycaemia, leading to delayed or impaired tissue repair. Computational techniques offer a promising avenue for unravelling the complexities of diabetic wound healing by elucidating the molecular mechanisms involved.</p><p><strong>Methodology: </strong>This study utilized in silico molecular docking and dynamics simulations to explore the potential therapeutic effectiveness of olivetol, a phenolic compound, in the context of diabetic wound healing. Furthermore, computational methodologies, encompassing pkCSM, Swiss ADME, OSIRIS® property explorer, PASS online web resource, and MOLINSPIRATION® software, were employed to forecast the pharmacokinetic properties, biological actions, and in vitro analyses, such as MTT and scratch assays, to evaluate the therapeutic effectiveness of olivetol in wound healing.</p><p><strong>Results and discussion: </strong>Our findings have revealed olivetol to be a promising candidate for targeting multiple pathways implicated in diabetic wound healing. Its ability to modulate inflammation, oxidative stress, extracellular matrix remodeling, angiogenesis, and cell signaling suggests a multifaceted approach to promoting effective wound repair. Moreover, olivetol has been found to demonstrate strong binding affinity with key MRSA target proteins, indicating its potential as an antimicrobial agent against MRSA infections in diabetic wounds. The in vitro MTT assay demonstrated cell viability with an IC50 value of 40.80 μM, highlighting its cytotoxicity potential. Additionally, the scratch assay confirmed promising wound healing activity, showcasing its effectiveness in promoting cell migration and closure.</p><p><strong>Conclusion: </strong>Olivetol emerges as a promising candidate for targeted interventions in non-healing diabetic wounds, particularly due to its ability to address prolonged inflammation, a common obstacle in diabetic wound healing.</p>","PeriodicalId":93962,"journal":{"name":"Current drug discovery technologies","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142362574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bridging the Gap: Quality by Design as a Catalyst for Enhanced Quality Management Systems in Biopharmaceutical Manufacturing. 缩小差距:质量源于设计--生物制药生产过程中质量管理系统提升的催化剂》(Quality by Design as a Catalyst for Enhanced Quality Management Systems in Biopharmaceutical Manufacturing)。
Pub Date : 2024-09-27 DOI: 10.2174/0115701638312326240918093333
Shivang Saxena, Shubhi Saxena, Diksha, Niraj S Patil, Animesh Ranjan, Amandeep Singh

The document emphasizes the importance of addressing key issues in Quality Management Systems (QMS) to stay competitive and provide high-quality goods and services in a dynamic market. It highlights the need to adopt novel quality management techniques for long-term success. The fundamentals of Quality by Design (QbD) are discussed, tracing back to pioneers like Joseph M. Juran and the Six Sigma concept for effective implementation. QbD is described as a systematic approach focusing on risk management, Quality Target Product Profile (QTPP), and Critical Quality Attributes (CQAs) to create products meeting predetermined quality standards. QbD incorporates quality concepts into the development and production processes. Its goal is to guarantee the quality of the product by determining and managing important factors. Manufacturers can be flexible with it while still adhering to strict quality standards. It signifies a change in the industry's paradigm.

该文件强调了解决质量管理体系(QMS)中的关键问题的重要性,以便在充满活力的市场中保持竞争力并提供高质量的产品和服务。文件强调了采用新型质量管理技术以取得长期成功的必要性。书中讨论了质量源于设计(QbD)的基本原理,并追溯到约瑟夫-M-朱兰(Joseph M. Juran)等先驱以及有效实施六西格玛(Six Sigma)的概念。QbD 被描述为一种系统方法,重点关注风险管理、质量目标产品简介 (QTPP) 和关键质量属性 (CQA),以创造符合预定质量标准的产品。QbD 将质量概念融入开发和生产过程。其目标是通过确定和管理重要因素来保证产品质量。制造商可以灵活运用 QbD,同时仍然遵守严格的质量标准。它标志着行业范式的改变。
{"title":"Bridging the Gap: Quality by Design as a Catalyst for Enhanced Quality Management Systems in Biopharmaceutical Manufacturing.","authors":"Shivang Saxena, Shubhi Saxena, Diksha, Niraj S Patil, Animesh Ranjan, Amandeep Singh","doi":"10.2174/0115701638312326240918093333","DOIUrl":"https://doi.org/10.2174/0115701638312326240918093333","url":null,"abstract":"<p><p>The document emphasizes the importance of addressing key issues in Quality Management Systems (QMS) to stay competitive and provide high-quality goods and services in a dynamic market. It highlights the need to adopt novel quality management techniques for long-term success. The fundamentals of Quality by Design (QbD) are discussed, tracing back to pioneers like Joseph M. Juran and the Six Sigma concept for effective implementation. QbD is described as a systematic approach focusing on risk management, Quality Target Product Profile (QTPP), and Critical Quality Attributes (CQAs) to create products meeting predetermined quality standards. QbD incorporates quality concepts into the development and production processes. Its goal is to guarantee the quality of the product by determining and managing important factors. Manufacturers can be flexible with it while still adhering to strict quality standards. It signifies a change in the industry's paradigm.</p>","PeriodicalId":93962,"journal":{"name":"Current drug discovery technologies","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Comprehensive Investigation: Developing the Pharmaceutical Industry through Artificial Intelligence. 全面调查:通过人工智能发展制药业。
Pub Date : 2024-09-05 DOI: 10.2174/0115701638313233240830132804
Deepak Jain, Phool Chandra, Zeeshan Ali, Nishat Fatma, Hafsa Khan

AI's rise has affected many aspects of civilization. Pharmaceutical businesses have been hit hard. This review paper highlights AI's benefits for disease detection, clinical trials, medicine development, and productivity in the pharmaceutical industry. Pharmaceutical companies have built specialized systems to help doctors diagnose and monitor medication remediation. Pharmaceutical businesses are utilizing AI for machine learning to imitate human analytical processes for more accurate and insightful data. AI has many benefits for the pharmaceutical business. Data analysis can address previously insoluble problems due to improved precision. AI boosts productivity, lowers expenses, and enhances tasks. AI insights enhance understanding of user behavior, market performance, and clinical trial success. AI helps identify patients during clinical trials and improves antiviral detection to ensure efficacy, safety, cost-effectiveness, and seamless pharmaceutical procedures. The pharmaceutical industry emphasizes AI in R&D, drug discovery, diagnostics, sickness prevention, epidemic forecasting, remote access, manufacturing, and marketing. Artificial intelligence has transformed medication development and discovery by analyzing vast datasets, discovering complicated patterns, and forecasting efficacy. Pharmaceutical companies like Novartis, AstraZeneca, and Verge Genomics are utilizing AI for drug feature prediction, neurological evaluation, therapy development, pulmonary and hypertension recognition, low-cost medication production, and disease diagnosis.

人工智能的兴起影响了人类文明的许多方面。制药业受到了严重冲击。本评论文章重点介绍了人工智能在疾病检测、临床试验、药品开发和制药业生产率方面的优势。制药公司建立了专门的系统来帮助医生诊断和监控药物治疗。制药企业正在利用人工智能进行机器学习,以模仿人类的分析过程,从而获得更准确、更有洞察力的数据。人工智能对制药业有很多好处。由于提高了精确度,数据分析可以解决以前无法解决的问题。人工智能可提高生产率、降低成本并改进任务。人工智能的洞察力可增强对用户行为、市场表现和临床试验成功的理解。人工智能有助于在临床试验期间识别患者,并改进抗病毒检测,以确保疗效、安全性、成本效益和无缝制药程序。制药业在研发、药物发现、诊断、疾病预防、流行病预测、远程访问、制造和营销方面都重视人工智能。人工智能通过分析庞大的数据集、发现复杂的模式和预测疗效,改变了药物研发和发现。诺华(Novartis)、阿斯利康(AstraZeneca)和Verge Genomics等制药公司正在利用人工智能进行药物特征预测、神经系统评估、疗法开发、肺部和高血压识别、低成本药物生产和疾病诊断。
{"title":"A Comprehensive Investigation: Developing the Pharmaceutical Industry through Artificial Intelligence.","authors":"Deepak Jain, Phool Chandra, Zeeshan Ali, Nishat Fatma, Hafsa Khan","doi":"10.2174/0115701638313233240830132804","DOIUrl":"https://doi.org/10.2174/0115701638313233240830132804","url":null,"abstract":"<p><p>AI's rise has affected many aspects of civilization. Pharmaceutical businesses have been hit hard. This review paper highlights AI's benefits for disease detection, clinical trials, medicine development, and productivity in the pharmaceutical industry. Pharmaceutical companies have built specialized systems to help doctors diagnose and monitor medication remediation. Pharmaceutical businesses are utilizing AI for machine learning to imitate human analytical processes for more accurate and insightful data. AI has many benefits for the pharmaceutical business. Data analysis can address previously insoluble problems due to improved precision. AI boosts productivity, lowers expenses, and enhances tasks. AI insights enhance understanding of user behavior, market performance, and clinical trial success. AI helps identify patients during clinical trials and improves antiviral detection to ensure efficacy, safety, cost-effectiveness, and seamless pharmaceutical procedures. The pharmaceutical industry emphasizes AI in R&D, drug discovery, diagnostics, sickness prevention, epidemic forecasting, remote access, manufacturing, and marketing. Artificial intelligence has transformed medication development and discovery by analyzing vast datasets, discovering complicated patterns, and forecasting efficacy. Pharmaceutical companies like Novartis, AstraZeneca, and Verge Genomics are utilizing AI for drug feature prediction, neurological evaluation, therapy development, pulmonary and hypertension recognition, low-cost medication production, and disease diagnosis.</p>","PeriodicalId":93962,"journal":{"name":"Current drug discovery technologies","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142142110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current drug discovery technologies
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1